“ Numerous phagocytosis checkpoints and ‘do not eat me’ signals (i.e., CD47, CD24, MHC-I, PD-L1, STC1, and GD2) have recently been recognized as potential therapeutic targets. ”
BUFFALO, NY- September 11, 2024 – A new editorial was recently published in Oncotarget's Volume 15 , on July 10, 2024, entitled, “ The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy .”
As discussed in this paper, the growing understanding of the tumor immune microenvironment (TME) and its impact on treatment outcomes has led to advances in cancer therapy aimed at enhancing antitumor immune responses. While most current immunotherapies focus on T cells and immune checkpoint inhibitors (ICIs), there is increasing interest in targeting innate immune components, such as macrophages. Tumor-associated macrophages (TAMs) support tumor growth, metastasis, and angiogenesis, making them key targets for novel immunotherapies aimed at shifting the M2-like (pro-tumoral) macrophages to the M1-like (antitumoral) phenotype.
In their editorial, researchers Maria Gracia-Hernandez, Manasa Suresh, and Alejandro Villagra from Georgetown University Medical Center , highlight key phagocytosis checkpoints and “do not eat me” signals—such as CD47, CD24, MHC-I, PD-L1, STC1, and GD2—that have emerged as potential therapeutic targets.
The authors note that many tumor types overexpress CD47 to evade phagocytosis by interacting with SIRPα on macrophages. The editorial also summarizes challenges in targeting CD47 and potential solutions to overcome these obstacles.
“ Overall, our understanding of this significant ‘do not eat me’ pathway over the years has resulted in the development of novel therapies and strategies to boost innate antitumor activity .”
Continue reading: DOI: https://doi.org/10.18632/oncotarget.28607
Correspondence to: Alejandro Villagra - alejandro.villagra@georgetown.edu
Video short: https://www.youtube.com/watch?v=MrJurw8gYj4
Keywords: cancer, immunotherapy, macrophages, CD47, HDACs
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget :
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline , PubMed Central , Scopus , EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify , and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries , please contact media@impactjournals.com .
Oncotarget Journal Office
6666 East Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
Oncotarget
Commentary/editorial
Not applicable
The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy
10-Jul-2024
Authors have no conflicts of interest to declare.